LADENBURG, Germany I May 27, 2025 I Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), ...

PARIS, France I May 27, 2025 I Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., ...

DUBLIN, Ireland I May 23, 2025 I Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients ...

ROCKVILLE, MD, USA I May 22, 2025 I AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the ...

COPENHAGEN, Denmark I May 22, 2025 I Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ ...

ASC50 is an in-house discovered and developed oral small molecule interleukin-17 (IL-17) inhibitor for the treatment of multiple autoimmune and ...

On January 7th, 2025, DualityBio and Avenzo announced that they entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418, a ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – ...

PHILADELPHIA, PA, USA I May 22, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala ...

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the ...

Orionis to receive $105 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for the discovery of small-molecule monovale ...

BAY 3670549 is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor with potential to help control ...